Get regular updates to your inbox.
An investigational therapy called R-107 completely stopped the progression of pulmonary arterial hypertension (PAH) in a rat model and may become the first medicine to reverse the increasing blood pressure characteristic of the disease, a study suggested. Now, R-107’s developer, Claritas Pharmaceuticals, plans to begin clinical testing…
In people experiencing a pulmonary embolism, higher-than-normal arterial stiffness at the time of hospital discharge increased the risk of pulmonary arterial hypertension (PAH) when evaluated one month later, according to a study in Italy. Given that this patient population is at risk of chronic thromboembolic pulmonary hypertension…
AllianceRx Walgreens Prime, a specialty and home delivery pharmacy, is partnering with TailorMed, a healthcare technology company, to help lower out-of-pocket prescription costs for specialty pharmacy patients. Medications attained through specialty pharmacies are those used to treat rare and chronic conditions in the U.S., and are often extremely costly. For…
An upcoming series of educational virtual events for people with pulmonary arterial hypertension (PAH) and their caregivers will offer insights and perspectives about how to manage life with PAH. The National Broadcast Series will include three talks from August to October. Each of the one-hour talks is scheduled to…
TPN171H, an experimental oral therapy for pulmonary arterial hypertension (PAH), was generally safe and showed a favorable pharmacological profile in healthy volunteers, according to data from a Phase 1 clinical trial. The therapy — previously reported to be a more potent and selective PDE5 suppressor than sildenafil in…
A protein known as cell division cycle protein 2 (CDC2) enhances the proliferation of pulmonary artery smooth muscle cells — those lining the walls of lung arteries — in people with pulmonary arterial hypertension (PAH), a study reported. Additionally, the increased level of CDC2 in these cells was found…
The PAPi blood pressure test was able to accurately predict mortality in Asian people with pulmonary arterial hypertension (PAH), a 14-year study revealed. Despite that finding, the multi-factor REVEAL score was found to still be the best predictor for mortality risk in PAH. “In our analysis, low PAPi was…
Nominations are now open for the worldwide 2022 Black Pearl Awards from Eurordis-Rare Diseases Europe. The 12 award categories recognize individual advocates, policy makers, researchers, organizations, and companies who work to make a difference for the global rare disease community. The deadline for nominations is Sept. 10…
U.S. veterans infected with the human immunodeficiency virus (HIV) — the virus that causes AIDS — are at higher risk of pulmonary hypertension (PH), according to a large study in this population. “HIV infection had a direct effect on incident pulmonary hypertension among US veterans,” including those with no history…
Non-alcoholic fatty liver disease (NAFLD) — an umbrella term for conditions caused by a buildup of fat in the liver — is about twice as common among people who have pulmonary hypertension (PH) than among those who do not, a review of almost 19,000 people has shown. The finding…
The likelihood of developing pulmonary hypertension (PH) is low among people in southern Italy, a study drawn from a random and large grouping of individuals with echocardiograms, done to determine disease prevalence, suggested. Independent predictors of PH include female sex and right ventricular enlargement, its scientists noted. The study, “…
Get regular updates to your inbox.